Skip to main content

Baxter International Value Stock - Dividend - Research Selection

Baxter international

ISIN: US0718131099 , WKN: 853815

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors\' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Artisan Mid Cap Value Fund’s Views on Baxter International (BAX)

2026-01-05
Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund’s Investor Class fund ARTQX returned 0.97%, Advisor Class fund APDQX posted a return of 0.98%, and Institutional Class fund APHQX returned 0.97%, compared to […]

Assessing Baxter International (BAX) Valuation After Recent Share Price Momentum And Margin Concerns

2026-01-05
Baxter International (BAX) has drawn fresh investor attention after recent trading, with the share price at $19.50 and mixed returns over the month and past 3 months prompting closer scrutiny of its fundamentals. See our latest analysis for Baxter International. The recent 1 day share price return of 2.04% and 1 month share price return of 5.18% sit against a 1 year total shareholder return decline of 33.07%. This indicates that short term momentum is improving, while longer term performance...

How Investors May Respond To Baxter (BAX) Retiring Near‑Term Debt And Advancing Connected Infusion Therapy

2026-01-04
In December 2025, Baxter International Inc. completed the final settlement of its cash tender offers, retiring all of its 2.600% senior unsecured notes due 2026 and purchasing a substantial portion of its 1.915% senior unsecured notes due 2027 for up to US$600,000,000 in aggregate, including US$2,610,000 of 2026 notes bought at US$960.50 per US$1,000 of principal plus accrued interest. By reducing near-term debt obligations through these tender offers, Baxter has adjusted its balance sheet...

What Do Analysts Think About Baxter International Inc. (BAX)?

2026-01-02
Baxter International Inc. (NYSE:BAX) is one of the top cheap stocks under $20 to buy now. On December 12, Wells Fargo analyst Larry Biegelsen reiterated a Hold rating on Baxter International Inc. (NYSE:BAX) on December 12 and set a price target of $19.00. The rating update came after Baxter International Inc. (NYSE:BAX) announced on December […]

ICU Medical: Difficult Transition, A More Interesting Company (Upgrade)

2025-12-30
ICU Medical stock is poised for growth and margin gains post-integration. Here's what investors need to know.

Opportunities and Competition in the $1.19 Billion U.S. IV Bags Market, 2025-2033, Featuring Baxter International, Kraton, Technoflex, B. Braun Medical, Sippex IV Bags and More

2025-12-29
Non-PVC, environmentally friendly IV bags are gaining traction due to regulatory and health trends U.S. IV Bags Market U.S. IV Bags Market Dublin, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The "United States IV Bags Market Report by Material Type, Capacity, Chamber Type, States and Company Analysis, 2025-2033" has been added to ResearchAndMarkets.com's offering.The United States IV Bags Market is expected to grow substantially, increasing from US$ 595.98 million in 2024 to US$ 1.19 billion in 2033. This

Reasons to Retain Baxter International Stock in Your Portfolio Now

2025-12-26
BAX is reshaping its portfolio following the divestiture of Kidney Care, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.

Baxter International Inc. (BAX): A Bull Case Theory

2025-12-18
We came across a bullish thesis on Baxter International Inc. on Value investing subreddit by Mr-Gambini. In this article, we will summarize the bulls’ thesis on BAX. Baxter International Inc.’s share was trading at $19.29 as of December 17th. BAX’s forward P/E was 8.12 according to Yahoo Finance. Baxter International (BAX) is a quintessential “boring but essential” medtech company operating in oligopolistic markets for […]

BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care

2025-12-15
Baxter shows EMR-integrated smart pumps cut safety alerts and speed IV setup, backed by real-world data from over a million infusions at ASHP 2025.

Baxter International Stock: Is BAX Underperforming the Health Care Sector?

2025-12-12
Baxter International has lagged the broader health care sector by a wide margin over the past year, and analysts are taking a guarded stance on its outlook.